

## **Product datasheet for TL304163V**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Granzyme H (GZMH) Human shRNA Lentiviral Particle (Locus ID 2999)**

**Product data:** 

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Granzyme H (GZMH) Human shRNA Lentiviral Particle (Locus ID 2999)

**Locus ID:** 2999

**Synonyms:** CCP-X; CGL-2; CSP-C; CTLA1; CTSGL2

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** GZMH - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC027974, NM 001270780, NM 001270781, NM 033423, NM 033423.1, NM 033423.2,

NM 033423.3, NM 033423.4, NM 001270781.1, NM 001270780.1, NM 033423.5,

NM 001270780.2, NM 001270781.2

UniProt ID: P20718

**Summary:** This gene encodes a member of the peptidase S1 family of serine proteases. Alternative

splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate a chymotrypsin-like protease. This protein is reported to be constitutively expressed in the NK (natural killer) cells of the immune system and may play a role in the cytotoxic arm of the innate immune response by inducing target cell death and by directly cleaving substrates in pathogen-infected cells. This gene is present in a gene cluster with another member of the granzyme subfamily on chromosome 14.

[provided by RefSeq, Nov 2015]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







**Guaranteed:** 

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).